Voyager Therapeutics

Voyager Therapeutics is a clinical-stage gene therapy company focused on developing treatments for patients suffering from severe neurological diseases. The company's pipeline consists of six programs for severe neurological indications, including: VY-AADC for the treatment of Parkinson's disease; VY-SOD101 for the treatment of monogenic form of amyotrophic lateral sclerosis; VY-FXN01 for the treatment of Friedreich's Ataxia; VY-HTT01 for the treatment of Huntington's disease; Tau Program for the treatment of tauopathies, including Alzheimer's disease, frontotemporal dementia, and progressive supranuclear palsy; and VY-NAV01 for the treatment of severe, chronic pain.
  • TickerVYGR
  • ISINUS92915B1061
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

ValuEngine Rating and Forecast Report for VYGR

ValuEngine Rating and Forecast Report for VYGR

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

David Nierengarten ...
  • Jeffrey La Rosa
  • Matthew Barcus

2Q19; Looking Ahead to Huntington’s Disease IND Filing Late This Year

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

David Nierengarten ...
  • Jeffrey La Rosa
  • Matthew Barcus

2Q19; Looking Ahead to Huntington’s Disease IND Filing Late This Year

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

1 director sold

A director at Voyager Therapeutics Inc sold 2,451 shares at 18.380USD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The...

ValuEngine Rating and Forecast Report for VYGR

ValuEngine Rating and Forecast Report for VYGR

ValuEngine Rating and Forecast Report for VYGR

ValuEngine Rating and Forecast Report for VYGR

ValuEngine Rating and Forecast Report for VYGR

ValuEngine Rating and Forecast Report for VYGR

ValuEngine Rating and Forecast Report for VYGR

ValuEngine Rating and Forecast Report for VYGR

ValuEngine Rating and Forecast Report for VYGR

ValuEngine Rating and Forecast Report for VYGR

ResearchPool Subscriptions

Get the most out of your insights

Get in touch